Literature DB >> 14555579

Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome.

Ana del Río1, Ignasi Anguera, José M Miró, Lluis Mont, Vance G Fowler, Manel Azqueta, Carlos A Mestres.   

Abstract

BACKGROUND: Cardiac device (CD) endocarditis is an infrequent but potentially lethal infectious complication of permanent pacemakers or implantable cardioverter-defibrillators (ICDs), and mortality rates of 30 to 35% have been reported. Medical treatment has been suggested for the treatment of CD endocarditis, but there is increasing evidence that surgical treatment is to be preferred as the best approach to achieve eradication of the infection and reduce mortality.
OBJECTIVE: To evaluate the following: (1) the clinical and echocardiographic characteristics of patients with pacemaker or ICD endocarditis, (2) the outcome of this population depending on the mode of treatment (medical vs surgical treatment), and (3) the clinical, microbiological, echocardiographic, and therapeutic variables associated with patient outcome.
DESIGN: Prospective cohort study.
SETTING: Tertiary referral center in Barcelona, Spain. PATIENTS: All consecutive patients with infectious endocarditis (IE) admitted to the study institution between 1990 and 2001 were prospectively evaluated by a multidisciplinary treatment team, and a definite diagnosis of CD endocarditis was established when cases met pathologic or clinical criteria according to the Duke criteria.
RESULTS: A total of 31 patients, 25 men and 6 women aged 61 +/- 15 years (mean +/- SD), with pacemaker or ICD endocarditis were identified among 669 consecutive patients (4.6%) with IE. During the study period, a total of 3,768 pacemakers and 460 ICDs were implanted in the study institution. In 22 cases of pacemaker endocarditis, the pacemaker was implanted in our institution, and 9 cases were referred from other institutions (incidences of endocarditis on pacemaker and ICD implanted in our institution of 0.58% and 0.65%, respectively). Medical treatment without removal of the pacing system was initially performed on seven patients; all of them (100%) had relapses of endocarditis, and one patient died. The remaining 24 patients underwent surgical removal of the pacing system; 1 patient had one relapse, 3 patients died after surgical treatment, and the others were successfully cured with no relapses after a mean follow-up of 38 +/- 9 months. Clinical, echocardiographic, microbiological, and therapeutic variables were evaluated in association with prognosis. The only prognostic factor for failure of treatment or mortality was the absence of surgical treatment (p < 0.0001).
CONCLUSIONS: Electrode lead endocarditis occurred in < 1% of pacemaker and ICD implants. Conservative treatment without explantation of all hardware failed in all patients, and surgical treatment during antibiotic therapy was effective in eradication of infection but was associated with a 12.5% mortality. The only patient characteristic associated with treatment failure or death was the absence of surgical removal of all infected hardware. Complete extraction of the pacemaker or ICD should be considered as standard therapy for most patients with CD endocarditis.

Entities:  

Mesh:

Year:  2003        PMID: 14555579     DOI: 10.1378/chest.124.4.1451

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  32 in total

Review 1.  Current trends in the management of cardiac implantable electronic device (CIED) infections.

Authors:  Emanuele Durante-Mangoni; Irene Mattucci; Federica Agrusta; Marie-Françoise Tripodi; Riccardo Utili
Journal:  Intern Emerg Med       Date:  2012-06-29       Impact factor: 3.397

2.  Complete removal of infected devices and simultaneous implantation of new devices for infective endocarditis after pacemaker implantation.

Authors:  Takuya Miura; Kazushige Inoue; Takenori Yokota; Takashi Iwata; Masao Yoshitatsu
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-07-31

3.  Septic shock induced from an implantable cardioverter-defibrillator lead-associated Candida albicans vegetation.

Authors:  Sandeep Hindupur; Anthony J Muslin
Journal:  J Interv Card Electrophysiol       Date:  2005-10       Impact factor: 1.900

4.  Successful removal of an infected pacemaker lead using cardiopulmonary bypass in an 89-year-old patient.

Authors:  Hiroomi Murayama; Takashi Watanabe; Naoki Kida; Takashi Yano; Keiji Ohara; Atsukata Kobayashi
Journal:  J Artif Organs       Date:  2005       Impact factor: 1.731

5.  Very late-onset lead-associated endocarditis.

Authors:  Min-Soo Cho; Sung-Hwan Kim; Gi-Byoung Nam; Kee-Joon Choi; You-Ho Kim
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

6.  Cardiac Implantable Electronic Device Infection in Patients at Risk.

Authors:  Khaldoun G Tarakji; Christopher R Ellis; Pascal Defaye; Charles Kennergren
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-05

7.  Tricuspid-valve repair for pacemaker leads endocarditis.

Authors:  Federica Iezzi; Roberto Cini; Paolo Sordini
Journal:  BMJ Case Rep       Date:  2010-12-20

Review 8.  Surgical management of cardiac implantable electronic device infections.

Authors:  Michael Koutentakis; Stavros Siminelakis; Panagiotis Korantzopoulos; Anastasios Petrou; Alexandra Petrou; Helen Priavali; Eleftheria Priavali; Andreas Mpakas; Helen Gesouli; Eleftheria Gesouli; Efstratios Apostolakis; Eleftheria Apostolakis; Kosmas Tsakiridis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Nikolaos Machairiotis; Theodora Tsiouda; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

9.  New perspectives of infections in cardiovascular disease.

Authors:  Ignatius W Fong
Journal:  Curr Cardiol Rev       Date:  2009-05

10.  Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial.

Authors:  Jose M Tolosana; Paola Berne; Lluis Mont; Magda Heras; Antonio Berruezo; Joan Monteagudo; David Tamborero; Begoña Benito; Josep Brugada
Journal:  Eur Heart J       Date:  2009-05-31       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.